Marine Bioactive Compounds with Neuroprotective Potential

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 1829

Special Issue Editor


E-Mail Website
Guest Editor
G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia
Interests: cells of the immune system; the molecular mechanism of action; membrane receptors; neurodegenerative disorders; cytoptotection; inflammation; new drug discovery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,                

Neurodegenerative disorders are the second leading cause of death worldwide and the first leading cause of disability. The most common diseases affecting the brain are Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis. Due to the high mortality and incidence of neurological disorders, preventive and therapeutic strategies are critical. Currently, no effective pharmacological treatment has been proposed that would block or treat the progression of neurodegenerative diseases. Conventional medications prescribed to treat neurological disorders are associated with various side effects; consequently, in recent years, many researchers have considered the possible therapeutic effects of natural products on neurological diseases. The search and development of new approaches and drugs for their treatment is an extremely urgent task. In recent years, natural compounds of marine origin have been of great interest for their structural diversity and wide range of biological activity. In addition to antioxidant, anti-inflammatory, antiproliferative, antidiabetic, and cardioprotective properties, biocompounds of a marine origin have also shown neuroprotective activity.

Thus, through the utilization of the biological functions of the most intensively studied biocompounds as potential drugs for neurodegenerative disorders, marine pharmacology is constantly proving its potential in the field of biomedicine.

This Special Issue is intended to present ongoing research into the neuroprotective properties of marine natural compounds. We particularly welcome papers evaluating the molecular mechanisms of action of marine-derived compounds and their analogues. Also of interest are works on the isolation and structure determination of new compounds of marine origin with neuroprotective activity in the latest in vitro and in vivo models in the field of neurodegenerative disease research.

Dr. Evgeny A. Pisliagin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • new drug discovery and development
  • neuroinflammation
  • neurodegenerative diseases
  • marine biologically active compounds
  • neuroprotection
  • central nervous system (CNS) disorders
  • Alzheimer’s disease (AD)
  • Parkinson’s disease (PD)
  • schizophrenia
  • dementia

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 9005 KiB  
Article
Porphyran Attenuates Neuronal Loss in the Hippocampal CA1 Subregion Induced by Ischemia and Reperfusion in Gerbils by Inhibiting NLRP3 Inflammasome-Mediated Neuroinflammation
by Dae Won Kim, Tae-Kyeong Lee, Ji Hyeon Ahn, Se-Ran Yang, Myoung Cheol Shin, Jun Hwi Cho, Moo-Ho Won, Il Jun Kang and Joon Ha Park
Mar. Drugs 2024, 22(4), 170; https://doi.org/10.3390/md22040170 - 11 Apr 2024
Viewed by 1512
Abstract
Porphyran, a sulfated polysaccharide found in various species of marine red algae, has been demonstrated to exhibit diverse bioactivities, including anti-inflammatory effects. However, the protective effects of porphyran against cerebral ischemia and reperfusion (IR) injury have not been investigated. The aim of this [...] Read more.
Porphyran, a sulfated polysaccharide found in various species of marine red algae, has been demonstrated to exhibit diverse bioactivities, including anti-inflammatory effects. However, the protective effects of porphyran against cerebral ischemia and reperfusion (IR) injury have not been investigated. The aim of this study was to examine the neuroprotective effects of porphyran against brain IR injury and its underlying mechanisms using a gerbil model of transient forebrain ischemia (IR in the forebrain), which results in pyramidal cell (principal neuron) loss in the cornu ammonis 1 (CA1) subregion of the hippocampus on day 4 after IR. Porphyran (25 and 50 mg/kg) was orally administered daily for one week prior to IR. Pretreatment with 50 mg/kg of porphyran, but not 25 mg/kg, significantly attenuated locomotor hyperactivity and protected pyramidal cells located in the CA1 area from IR injury. The pretreatment with 50 mg/kg of porphyran significantly suppressed the IR-induced activation and proliferation of microglia in the CA1 subregion. Additionally, the pretreatment significantly inhibited the overexpressions of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing protein-3 (NLRP3) inflammasome complex, and pro-inflammatory cytokines (interleukin 1 beta and interleukin 18) induced by IR in the CA1 subregion. Overall, our findings suggest that porphyran exerts neuroprotective effects against brain IR injury, potentially by reducing the reaction (activation) and proliferation of microglia and reducing NLRP3 inflammasome-mediated neuroinflammation. Full article
(This article belongs to the Special Issue Marine Bioactive Compounds with Neuroprotective Potential)
Show Figures

Figure 1

Back to TopTop